-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Set cell lymphoma (MCL) is usually an aggressive and rare form of non-Hodgkin's lymphoma (NHL), accounting for nearly 6 percent of all NHL cases, and is mostly diagnosed in men in their 60s.
the median non-progressive survival of patients treated with calabrutinib (MCL) with recurring or refractic heterocytic lymphoma (MCL) continued for 22 months, based on long-term follow-up.
follow-up for 38.1 months, and 44% of patients continued to receive treatment.
results presented at the 62nd annual meeting of the American Society of Hematology (ASH) also showed consistent safety and toerability of the drug, with only 14 patients (11 percent) discontinued treatment due to adverse events.
Wang Luhua, a professor in the lymphoma/myeloma department at the University of Texas Anderson Cancer Center, commented on the results: "Sleeve lymphoma is an invasive, hard-to-treat blood cancer that is usually diagnosed at an advanced stage and often resistant to treatment.
data show that patients treated with acalabrutinib develop deep reactions over time, while the safety profile remains essentially the same, including a lower rate of 3/4 heart events and bleeding events."
。
